<DOC>
	<DOCNO>NCT00003388</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist liposomal doxorubicin , cyclophosphamide , vincristine , prednisone treat patient AIDS-related lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With AIDS-Related Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine one year survival complete response rate patient treat doxorubicin HCl liposome/cyclophosphamide/vincristine/prednisone ( Doxil-CVP ) AIDS-related lymphoma . II . Evaluate toxicity combination chemotherapy regimen , Doxil-CVP , patient population . III . Evaluate progression free overall survival treatment Doxil-CVP patient population . IV . Evaluate effect treatment Doxil-CVP plasma viral mRNA level , CD4+ lymphocyte count , incidence type opportunistic infection patient population . OUTLINE : Patients stratify accord disease characteristic . All patient receive 30 minute infusion doxorubicin HCl liposome IV , cyclophosphamide IV , vincristine IV day 1 . Patients also receive oral prednisone day 1-5 . Filgrastim ( G-CSF ) administer subcutaneously start day 6 continue absolute neutrophil count least 10,000/mm3 . Treatment course repeat every 21 day . Patients lymphomatous bone marrow involvement and/or category J lymphoma receive cytarabine methotrexate intrathecally weekly 4 week . Patients lymphomatous meningitis receive whole brain irradiation alternate intrathecal chemotherapy regimen . A minimum 4 maximum 8 course administer . Patients remove study progressive disease , stable disease 4 course , life threatening infection would delay treatment 6 week , delay , except due neutropenia , chemotherapy treatment 6 week . Patients achieve complete response receive additional 2 course therapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 38 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm AIDSrelated nonHodgkin 's lymphoma intermediate high grade histologic type Anaplastic large cell lymphoma allow Must HIV positive Must least one objective measurable evaluable disease parameter No parenchymal CNS involvement lymphoma ( meningeal lymphoma allow ) A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : ( Except patient lymphomatous marrow involvement ) Absolute neutrophil count least 1000/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 5.0 mg/dL Renal : Creatinine le 3.0 mg/dL Cardiovascular : Patients history heart disease , evidence congestive heart failure , radiographic evidence cardiomegaly , electrocardiographic evidence prior myocardial infarction must LVEF least low limit normal Neurologic : No grade 3 great peripheral neuropathy Other : No prior concurrent malignancy Kaposi 's sarcoma , curatively treat basal cell squamous cell carcinoma skin , curatively treat carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception No history sensitivity E. coliderived protein PRIOR CONCURRENT THERAPY : Biologic therapy : At least 5 day since interferon therapy Chemotherapy : No prior cytotoxic chemotherapy except mucocutaneous Kaposi 's sarcoma At least 12 month since cytotoxic chemotherapy Kaposi 's sarcoma Endocrine therapy : Prior steroid allow No concurrent steroid therapy great 5 mg prednisone ( equivalent ) per day Radiotherapy : No prior radiotherapy except mucocutaneous Kaposi 's sarcoma Surgery : Not specify Other : No concurrent zidovudine ( AZT ) Concurrent antiretroviral medication AZT allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>